MTOR and Parkinson disease: Researchers are actively investigating various approaches, including small molecules capable of increasing α-syn clearance as mTOR inhibitor (including CCI-779 known as Temsirolimus; and AP23573, known as Ridaforolimus), gene therapies, and lifestyle interventions, to target autophagy as a potential therapeutic avenue for PD (Zhang K. et al., 2021).